检索结果-南通市图书馆

Etiological features of cirrhosis inpatients in Beijing, China

Chinese Medical Journal 2013年第13期126卷 2430-2434页

作者： song guang-jun feng bo rao hui-ying wei lai Peking University People's Hospital Peking University Hepatology Institute Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases Peking University Beijing 100044 China

Background The etiological spectrum of cirrhosis has changed over the years, but our knowledge of it is limited. The present study aimed to investigate the etiological features of cirrhosis inpatients and their variation in the past 18 years in Beijing. Methods A retrospective analysis was performed on all patients with cirrhosis diagnosed for the first time in Peking University People＇s Hospital from January 1, 1993, to October 25, 2010. Data were analyzed using SPSS 20.0. Results A total of 2119 cirrhosis inpatients were included in this study： 1412 （66.6%） male and 707 （33.4%） female. Chronic hepatitis B accounted for 58.7%; chronic hepatitis C for 7.6%; chronic hepatitis B and hepatitis C virus co-infection for 0.8% （16 cases）; alcoholic liver disease for 9.4% （200 cases）; and autoimmune diseases for 9.4% （199 cases）. In the past 18 years, the percentage of chronic hepatitis B has decreased from 75.2% to 48.7%; alcoholic liver disease has increased from 5.1% to 10.6%; and autoimmune disease has increased from 2.2% to 12.9%. The percentages of chronic hepatitis B and alcoholic liver disease were higher among men, whereas the percentages of chronic hepatitis C, autoimmune diseases and cryptogenic cirrhosis were higher among women. Conclusions Chronic hepatitis B was still the most common etiology of cirrhosis in China, but the percentage has been decreasing. The percentages of alcoholic liver disease and autoimmune diseases have been increasing. The etiological spectrum of cirrhosis inpatients differed significantly according to sex.

关键词： etiology, cirrhosis, hepatitis B hepatitis C autoimmune liver disease, alcoholic liver disease

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Effect of spleen operation on antiviral treatment in hepatitis Cvirus-related cirrhotic patients

引用

World Journal of Gastroenterology 2014年第41期20卷 15387-15397页

作者： bo feng wei Zhang Bi-Fen Luo guang-jun song Jian Wang Qian Jin Hong Qin lai wei Peking University People’s Hospital Peking University Hepatology Institute Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases

AIM: To investigate the impact of spleen operation (SO) on interferon-α (IFN-α)-based antiviral treatment in patients with hepatitis C virus (HCV)-related cirrhosis.

关键词： Hepatitis C virus cirrhosis Interferon Ribavirin Splenectomy Partial splenic embolization

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Effect of the Normal Baseline Levels ALT on the Outcome of the Antiviral Treatment in Na? ve Chronic Hepatitis C Patients:a Meta-analysis

Effect of the Normal Baseline Levels ALT on the Outcome of t...

引用

中华医学会第十六次全国病毒性肝炎及肝病学术会议

作者： guang jun song bo feng huiying rao wei Zhang Shaocai Du lai wei Peking University People's Hospita Peking University Hepatology Institute

Background The Objective of this meta-analysis was to estimate the effect of normal and abnormal ALT on the IFN-alpha based antiviral outcome in na? ve CHC *** We identified eligible studies by searching the relevant databases,published between January 2000 and May *** selection of eligible papers was carried out using a scoring system based on guidelines and inclusion *** Seven studies in-

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

核苷酸类似物抗病毒治疗对乙型肝炎肝硬化患者预后影响的荟萃分析

引用

中华肝脏病杂志 2013年第6期21卷 438-441页

作者：宋广军封波饶慧瑛王剑魏来北京大学人民医院肝病科北京大学肝病研究所 100044

目的了解核苷类似物抗病毒治疗对乙型肝炎肝硬化患者预后的影响。方法检索PubMed、EMBASE、theCochraneCentralRegisterofControlledTrials、中国期刊全文数据库、中国科技期刊数据库（维普）、万方数据化期刊全文数据库、中国生物医学... 详细信息

目的了解核苷类似物抗病毒治疗对乙型肝炎肝硬化患者预后的影响。方法检索PubMed、EMBASE、theCochraneCentralRegisterofControlledTrials、中国期刊全文数据库、中国科技期刊数据库（维普）、万方数据化期刊全文数据库、中国生物医学文献数据库1998年1月至2012年3月公开发表的有关乙型肝炎肝硬化患者抗病毒治疗的临床研究，共有7篇文献入选本研究，其中有l项高质量随机对照试验研究，4项队列研究，2项病例对照研究。应用Statall．0版软件对入选的研究进行Meta分析。结果Meta分析显示：（1）肝癌的发生率抗病毒治疗组为6．％（75／1116），对照组为11．2％（76／680），抗病毒治疗组肝癌的发生率明显低于对照组，OR=0．56，95％CI：0．40～0．79，P=0．001；（2）随访结束时的病死率抗病毒治疗组为10．8％（43／398），显著低于对照组的23．6％（78／331），抗病毒治疗随访结束时的病死率显著低于对照组，OR=0．36，95％CI：0．23～0．55，P=0．000。结论核苷类似物抗病毒治疗能显著降低乙型肝炎肝硬化患者肝癌的发生率和病死率。

关键词：肝硬化肝炎,乙型,慢性治疗学癌,肝细胞预后核苷类似物

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

CEPC Technical Design Report

引用

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis bodrov Anton bogomyagkov Serge bondarenko Stewart boogert Maarten boonekamp Marcello borri Angelo bosotti Vincent boudry Mohammed boukidi Igor boyko Ivanka bozovic Giuseppe bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi junsong Cang Guofu Cao Jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen Hua-Xing Chen huirun Chen Jinhui Chen Ji-Yuan Chen Kai Chen Mali Chen Mingjun Chen Mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen wei Chen Xiang Chen Xiaoyu Chen Xin Chen Xun Chen Xurong Chen Ye Chen ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

引用

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-Bin Ling Qiao-Nan Shan Xu-Yong wei Rui Wang Chang-Ku Jia Li Zhuang Tian Shen Li-Min Ding Zhi-Dan Xu lai-Bang Luo Li-bo Sun guang-Ming Li Tai-Shi Fang Nan Jiang Kun Zhang Zhao-Jie Su Zhi-Hai Peng Ren Lang Tao Jiang Qiang He Lin-Sen Ye Yang Yang Yu-Ting He Wen-Zhi Guo Liu-Gen Lan Xu-Yong Sun Dong Chen Zhi-Shui Chen Da-wei Zhou Shao-jun Ye Qi-Fa Ye Min Tian Jian-Hua Shi bo Wang Jiang Liu Qian Lu wei rao Jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen Wang Lin Zhong Jing-Sheng Ma Qi-Gen Li Sheng-Dong Wu Chang-Jiang Lu Cai-De Lu Dong-Hua Zhang Xuan Wang Zi-Qiang Li Mu-Jian Teng jun-Jie Li Wen-Tao Jiang Jian-Hua Li Quan-Bao Zhang Ning-Qi Zhu Zheng-Xin Wang Kang He Qiang Xia Shao-Hua song Zhi-Ren Fu wei Qiu Guo-Yue Lv Rui-Peng song Ji-Zhou Wang Zheng Wang Jian Zhou Gang Chen ying-Peng Zhao Li Li Ze-Min Hu Qi-Jie Luo Zhong-Zhou Si Bin Xie Xiao-Shun He Zhi-Yong Guo Shu-Sen Zheng Xiao Xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

丙型肝炎肝硬化患者抗病毒疗效的影响因素分析

引用

传染病信息 2012年第2期25卷 104-106,114页

作者：封波李晓波房继莲马慧饶慧瑛宋广军武楠王豪魏来北京大学人民医院北京大学肝病研究所 100044

目的探讨丙型肝炎肝硬化抗病毒治疗疗效影响因素。方法以干扰素(interferon,IFN)α为基础抗病毒治疗的丙型肝炎肝硬化患者作为研究对象,收集其流行病学资料、基线的相关化验指标、抗病毒治疗方案及经过。分析抗病毒治疗后获得的持续病... 详细信息

目的探讨丙型肝炎肝硬化抗病毒治疗疗效影响因素。方法以干扰素(interferon,IFN)α为基础抗病毒治疗的丙型肝炎肝硬化患者作为研究对象,收集其流行病学资料、基线的相关化验指标、抗病毒治疗方案及经过。分析抗病毒治疗后获得的持续病毒学应答(sustained virological response,SVR)率及其影响因素。结果 28例经IFNα联合利巴韦林抗病毒治疗的丙型肝炎肝硬化患者入选,9例获得了SVR,占32.1%。SVR组和非持续病毒学应答(non-SVR,N-SVR)组基线性别比例、年龄、感染时限、HCVRNA、转氨酶、中性粒细胞绝对计数、HGB、PLT和Child-Pugh评分均无统计学差异(P>0.05)。应用聚乙二醇干扰素(pegylated interferon,Peg-IFN)α患者的SVR率高于普通IFNα(P=0.003),但去除中途脱落的患者后2组SVR率的差异无统计意义(P=0.308)。依从性好的患者SVR率显著高于依从性差的患者(P=0.004)。普通IFNα治疗的患者终止治疗的比例显著高于Peg-IFNα(P=0.009),Child-Pugh评分高的患者终止治疗的比例显著高于Child-Pugh评分低的患者(P=0.034)。结论丙型肝炎肝硬化患者抗病毒治疗的SVR率较低,主要与其依从性差有关,而依从性与干扰素类型和肝硬化的严重程度有关。

关键词：丙型肝炎肝硬化干扰素利巴韦林

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

补肾清透方对慢性HBV携带者血清免疫因子的作用

引用

传染病信息 2012年第3期25卷 158-160页

作者：邢宇锋童光东贺劲松陈英杰张晓晖魏春山高辉周小舟邱梅徐文军郑颖俊徐韶敏陈亮唐海鸿张来占伯林马文峰孙新锋李群周大桥广州中医药大学深圳附属医院肝病科 518033

目的分析补肾清透方对慢性HBV携带者血清免疫因子的作用。方法选择符合慢性HBV携带诊断标准的患者400例,随机分为治疗组和对照组,每组200例。治疗组给予补肾清透方治疗,对照组给予安慰剂治疗,疗程52周。分别观察治疗前及治疗后血清HBV ... 详细信息

目的分析补肾清透方对慢性HBV携带者血清免疫因子的作用。方法选择符合慢性HBV携带诊断标准的患者400例,随机分为治疗组和对照组,每组200例。治疗组给予补肾清透方治疗,对照组给予安慰剂治疗,疗程52周。分别观察治疗前及治疗后血清HBV DNA定量和Th1/Th2型细胞因子[白细胞介素(interleukin,IL)-2、IL-4、IL-10和干扰素(interferon,IFN)γ]水平的变化。结果治疗52周后,治疗组血清HBV DNA下降>1 log10、>2 log10、>3 log10的患者比例明显高于对照组(P0.05)。治疗组Th1细胞因子IL-2和IFNγ水平明显升高(P<0.01),Th2细胞因子IL-4和IL-10水平明显下降(P<0.01),治疗前后差值与对照组比较差异有统计学意义(P<0.01)。结论补肾清透方对抑制慢性HBV携带者HBV的复制有一定作用,可能通过恢复特异性T细胞免疫功能而实现。

关键词：乙型肝炎病毒免疫因子中医药疗法

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

我国类风湿关节炎患者应用肿瘤坏死因子抑制剂现况调查

引用

北京大学学报（医学版） 2012年第2期44卷 182-187页

作者：王秀茹苏茵安媛周云杉张晓盈段天骄朱佳鑫李小峰王彩虹王莉枝王永福杨荣王国春卢昕朱平陈丽娜王轶王晓元靳洪涛刘金婷陈海英魏平王俊祥刘湘源孙琳崔刘福舒荣刘白鹭张卓莉李光韬李振彬杨静李俊芳贾彬张风肖陶杰梅林金盈韦美秋刘晓敏柯丹胡绍先叶丛韩淑玲杨岫岩李昊黄慈波高明赖蓓李兴福宋立军穆荣栗占国北京大学人民医院风湿免疫科北京100044 北京大学首钢医院多顶街社区卫生中心全科山西医科大学第二医院风湿免疫科太原030001 包头医学院第一附属医院风湿免疫科包头014010 中日友好医院风湿免疫科北京100029 第四军医大学西京医院风湿免疫科西安710032 兰州大学第二医院风湿免疫科兰州730030 河北医科大学第二医院风湿免疫科石家庄050000 河北医科大学第三医院风湿免疫科石家庄050051 北京大学第三医院风湿免疫科北京100191 华北煤炭医学院附属开滦医院风湿免疫科唐山063000 北京大学第一医院风湿免疫科北京100034 白求恩国际和平医院风湿免疫科石家庄050082 河北邯郸中心医院风湿免疫科邯郸056001 河北省人民医院风湿免疫科石家庄050051 广西壮族自治区人民医院风湿免疫科南宁530021 北京顺义区医院风湿免疫科北京101300 华中科技大学同济医学院附属同济医院风湿免疫科武汉430030 北京大学首钢医院风湿免疫科北京100144 中山医科大学附属第一医院风湿免疫科广州510080 北京医院风湿免疫科北京100730 山东大学齐鲁医院风湿免疫科济南250012

目的:了解我国类风湿关节炎(rheumatoid arthritis,RA)患者应用肿瘤坏死因子(tumor necrosis factor,TNF)抑制剂的现状以及影响其应用的因素。方法:采用多中心现况调查问卷调查的方法,记录入选者的一般情况和应用TNF抑制剂的情况,计算... 详细信息

目的:了解我国类风湿关节炎(rheumatoid arthritis,RA)患者应用肿瘤坏死因子(tumor necrosis factor,TNF)抑制剂的现状以及影响其应用的因素。方法:采用多中心现况调查问卷调查的方法,记录入选者的一般情况和应用TNF抑制剂的情况,计算患者应用TNF抑制剂的费用,分析我国TNF抑制剂的应用现状及影响其应用的相关因素。结果:2009年7月至2010年11月期间,共有全国范围内的21家大型医院风湿免疫科就诊的1 095位RA患者完成问卷,其中112位患者应用了TNF抑制剂(infliximab,商品名类克或etanercept,商品名益赛普)进行治疗,占总研究人群的10.2%(其中益赛普81例,占7.4%;类克26例,占2.4%;两种制剂都用过者5例,占0.5%)。应用类克疗程<3个月及3～6个月者均为38.1%,益赛普疗程<3个月及3～6个月者分别占38.5%和25.0%。应用类克疗程<3个月、3～6个月及6～9个月者的健康评估问卷(health assessment question-naire,HAQ)评分分别为1.1、0.5、0.1,益赛普的相应评分分别为1.3、1.0、0.3。应用类克疗程<3个月、3～6个月及6～9个月的费用分别为24 525.0、69 300.0、96 800.0元,益赛普的费用分别为7 394.8、9 158.6、54 910.9元。应用类克疗程<3个月、3～6个月及6～9个月的患者的间接经济损失分别为365.6、0、158.9元,益赛普分别为2 158.4、288.5、180.1元。出现过敏和感染的比例在应用益赛普者均为3.5%,在应用类克者均为6.5%。Logistic回归分析显示,受教育程度是影响TNF抑制剂应用的主要相关因素。结论:在我国大型医院就诊的RA患者中约有10%应用过TNF抑制剂,其病情随应用TNF抑制剂的疗程延长而减轻,治疗总费用随用药疗程延长而增加,但间接经济损失随疗程延长而减少,主要不良反应为过敏和感染,受教育程度是影响其应用的主要相关因素。

关键词：关节炎,类风湿肿瘤坏死因子问卷调查药费支出

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

全国多中心类风湿关节炎冠心病危险因素的现况调查

引用

北京大学学报（医学版） 2012年第2期44卷 176-181页

作者：李春王秀茹唐熠达安媛周云杉郭时伟张晓盈段天骄朱佳鑫李晓峰王莉枝王彩虹王永福杨荣王国春卢昕朱平陈丽娜靳洪涛刘金婷刘湘源孙琳陈海英魏平王俊祥崔刘福舒荣刘白鹭张卓莉李光韬李振彬杨静李俊芳贾彬张风肖陶杰梅韩淑玲林金盈韦美秋刘晓敏柯丹胡绍先叶丛杨岫岩李昊黄慈波高明赖蓓李兴福宋立军王轶王晓元穆荣苏茵栗占国北京大学人民医院风湿免疫科北京100044 北京大学首钢医院多顶街社区卫生中心全科中国医学科学院北京协和医学院阜外心血管病医院心内科北京100037 山西医科大学第二医院风湿免疫科太原030001 包头医学院第一附属医院风湿免疫科包头014010 中日友好医院风湿免疫科北京100029 第四军医大学西京医院风湿免疫科西安710032 河北医科大学第二医院风湿免疫科石家庄050000 北京大学第三医院风湿免疫科北京100191 河北医科大学第三医院风湿免疫科石家庄050051 华北煤炭医学院附属开滦医院风湿免疫科唐山063000 北京大学第一医院风湿免疫科北京100034 白求恩国际和平医院风湿免疫科石家庄050082 河北邯郸中心医院风湿免疫科邯郸056001 河北省人民医院风湿免疫科石家庄050051 北京大学首钢医院风湿免疫科北京100144 广西壮族自治区人民医院风湿免疫科南宁530021 北京顺义区医院风湿免疫科北京101300 华中科技大学同济医学院附属同济医院风湿免疫科武汉430030 中山医科大学附属第一医院风湿免疫科广州510080 北京医院风湿免疫科北京100730 山东大学齐鲁医院风湿免疫科济南250012 兰州大学第二医院风湿免疫科兰州730030

目的:了解我国类风湿关节炎(rheumatoid arthritis,RA)患者冠心病(coronary artery disease,CAD)的患病情况并评估其发生的危险因素。方法:调查RA患者冠心病相关的临床资料,包括冠心病的患病情况、冠心病传统危险因素[糖尿病、高血压、... 详细信息

目的:了解我国类风湿关节炎(rheumatoid arthritis,RA)患者冠心病(coronary artery disease,CAD)的患病情况并评估其发生的危险因素。方法:调查RA患者冠心病相关的临床资料,包括冠心病的患病情况、冠心病传统危险因素[糖尿病、高血压、高血脂、吸烟及体重指数(BMI)]及RA临床表现[关节肿胀、疼痛、畸形数目,皮下结节数目,动态红细胞沉降率(erythrocyte sedimentation rate,ESR)、C反应蛋白(C-reactive protein,CRP)、类风湿因子(rheumatoid factor,RF)等]、关节功能状态评分及用药情况。对冠心病组及非冠心病组的危险因素、临床特点及用药情况等方面进行单因素比较及多因素Logistic回归分析。结果:共调查21家医院的960例RA患者,其中女性779人,男性181人,女∶男=4.3∶1,平均年龄(52.7±13.9)岁(11.0～86.0岁)。RA患者冠心病的患病率为3.5%(34/960),其中合并超重和肥胖者占35.1%(377/960)、吸烟者占12.3%(118/960)、高血压者占17.0%(163/960)、糖尿病者占7.7%(74/960)、高胆固醇血症者占0.4%(4/960)、脑血管病者占3.0%(29/960)。冠心病组与非冠心病组相比,年龄高[(64.7±9.3)岁vs.(52.3±14.0)岁,P<0.001]、皮下结节数目多(14.7%vs.3.1%,P=0.005)、肺间质病变发生率高(17.6%vs.7.0%,P=0.034)、羟氯喹(hydroxychloroquine,HCQ)使用比例低(5.9%vs.22.6%,P=0.021)、糖尿病及高血压患病率高(29.4%vs.7.0%,P<0.001;38.2%vs.16.2%,P=0.001),而受检时关节畸形数目、RF水平及糖皮质激素的使用、高胆固醇血症患病率及BMI与冠心病发生无关。经多元Logistic回归分析,高龄、合并糖尿病及高血压为RA合并冠心病的独立危险因素,使用HCQ为RA合并冠心病的保护因素。结论:RA患者冠心病的患病率为3.5%。高龄、合并糖尿病及高血压为其独立危险因素,合并使用HCQ为其保护因素。

关键词：关节炎,类风湿冠心病危险因素患病率

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：